ClinicalTrials.gg
RecruitingNCT07625800SOLIUpdated Oct 30, 2026

Switch to Ofatumumab and Level of Immunoglobulins

An observational study in Multiple Sclerosis, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by University Hospital, Lille · Observational

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 30, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
115
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Multiple Sclerosis by University Hospital, Lille — 4 open to participants now, 4 under way, none of them phase 3. Multiple Sclerosis · University Hospital, Lille.

Started
2026
the only one that year
Observational
7 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Multiple Sclerosis by University Hospital, Lille, this one is the only one that started in 2026, is one of 7 observational ones, and was the 11th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

4 of the 11 studies in Multiple Sclerosis by University Hospital, Lille are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Multiple Sclerosis by University Hospital, Lille, or all of them as a file.
02

Study summary

This real-life study aims to describe IgG levels after switching from ocrelizumab 600 mg IV every 6 to 8 months in Patients with Multiple Sclerosis (PwMS) to ofatumumab 20 mg SC every month and showing a decreasing level of IgG during treatment by ocrelizumab in real life practice in France over 24 months of follow-up.

The primary objective is therefore to determine if the downward trend of IgG observed during ocrelizumab treatment is modified after a switch to ofatumumab, in PwMS treated during at least 18 months of ocrelizumab in real life practice, over 24 months of follow-up.

Read the detailed description

time perspective: retrospective and prospective

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Multiple Sclerosis
  • NIS
  • Ofatumumab
  • Kesimpta
  • Ocrelizumab
  • IgG
  • IgM
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will be adult patients with MS (women and men) who initiate treatment with ofatumumab after a treatment with ocrelizumab

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients (≥ 18 years old) who had been treated with ocrelizumab for a relapsing form of Multiple Sclerosis according to the ocrelizumab marketing authorization (MA) treatment regimen for at least 18 months.
  2. Patients with a decrease of IgG at a minimum of two consecutive dosages (around six months apart) during ocrelizumab treatment*.
  3. Patients already switched or switching from ocrelizumab to ofatumumab treatment (decision independent from the study*).
  4. Patients agreeing to participate to the study.
  5. Able to provide their non-opposition

    • At the discretion of the investigator, if a benefit for patients is expected based on their experience and depending on patient's characteristics

Exclusion criteria

Exclusion Criteria:

  1. Patients with ocrelizumab dose spacing > 8 months in the last 18 months before switch
  2. Patient who underwent an immunoglobulin supplementation therapy within 18 months before the switch
  3. Ongoing or planned pregnancy
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
115 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ofatumumab

    Adult patients (≥18 years) with relapsing multiple sclerosis treated with ocrelizumab for at least 18 months and already switched or switching from ocrelizumab to ofatumumab treatment

    Drug: ofatumumab

Interventions

  • There is no treatment allocation. Participants with MS that initiated treatment with ofatumumab (Kesimpta ®) as per neurologist practice and regardless of the study protocol.

06

What researchers measure

Primary outcomes

  1. Slope of serum immunoglobulin G (IgG) levels during ocrelizumab treatment period (minimum 18 months)

    Time frame: 42 months

  2. Slope of serum immunoglobulin G (IgG) levels during ofatumumab treatment period (24 months)

    Time frame: 42 months

Secondary outcomes

  1. Age at baseline (years)

    Time frame: Baseline

  2. Number and percentage of patients with stable serum IgG levels

    Time frame: 24 months

  3. Number of severe infections occurring during ocrelizumab treatment period prior to switch to ofatumumab

    Time frame: 18 months

  4. Slope of serum immunoglobulin M (IgM) levels during ocrelizumab treatment period (minimum 18 months)

    Time frame: 24 months

  5. Distribution of Expanded Disability Status Scale (EDSS) scores after switch to ofatumumab

    Expanded Disability Status Scale (EDSS): score range 0-10, where higher scores indicate greater neurological disability (worse outcome).

    Time frame: 24 months

  6. Number of patients who discontinued ofatumumab before the end of follow-up

    Time frame: 24 months

  7. Number and type of adverse events (AEs) during ofatumumab follow-up period

    Time frame: 24 months

  8. Disease duration (years since diagnosis)

    Time frame: Baseline

  9. Sex distribution (male/female, percentage of patients)

    Time frame: Baseline

  10. Number and percentage of patients with increased serum IgG levels

    Time frame: 24 months

  11. Slope of serum immunoglobulin M (IgM) levels during ofatumumab treatment period (24 months)

    Time frame: 24 months

  12. Distribution of Fatigue Severity Scale (FSS) scores after switch to ofatumumab

    Fatigue Severity Scale (FSS): score range 9-63, where higher scores indicate greater fatigue severity (worse outcome).

    Time frame: 24 months

  13. Distribution of Multiple Sclerosis Functional Composite (MSFC) scores after switch to ofatumumab

    Multiple Sclerosis Functional Composite (MSFC): standardized composite score (z-score), with higher scores indicating better neurological function (better outcome).

    Time frame: 24 months

  14. Number of relapses per patient after switch to ofatumumab

    Time frame: 24 months

  15. Reasons for discontinuation of ofatumumab before the end of follow-up

    Time frame: 24 months

  16. Number and type of serious adverse events (SAEs) during ofatumumab follow-up period

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jun 2029, 32 months after the start.

Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 32 months is below that.

Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2026, on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
Jun 4, 2026
StartActual
Oct 12, 2026was Jun 2026
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2029
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 30, 2026
Sites
CHU de Lille is now Recruiting
Oct 30, 2026
Start date
Jun 2026→Oct 12, 2026 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Recruiting
    CHU de Lille is now Recruiting
    Start date Jun 2026→Oct 12, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07625800
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Oct 12, 2026
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

PATRICK VERMERSCH, Pr
Contact
patrick.vermersch@chu-lille.fr
06.33.38.32.60

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion